An update on drug interactions by Livingston MG, Livingston HM Department of Psychological Medicine, University of Glasgow, Scotland. Despite their clinical benefits, this has led to a reduction in use of such medications. Discovery of the 2 main subgroups of monoamine oxidase, types A and B, led to the synthesis of MAOIs selective for one or other of these isoenzymes. This drug is useful in the treatment of the early stages of the disease and later on as an adjunct to other drug therapies. Although these newer drugs represent an advance in safety, their use has, as yet, only been established in the treatment of depression.
RIMAs also retain a potential for adverse interaction with other drugs.
Concomitant prescription of serotonin-enhancing drugs should only be undertaken with caution for patients on moclobemide, toloxatone or selegiline.